Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -8 of 8
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
Last Modified:
6/28/2006
 
First Published:
3/1/1999
1.
Phase I/II Study of Ras Peptide Cancer Vaccine With or Without Interleukin-2 in HLA-A2-1-Positive Patients With Locally Advanced or Metastatic Colorectal Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Completed
Over 18
NCI
NCI-99-C-0023L
NCI-T98-0034, NCT00019591, T98-0034
Last Modified:
4/20/2007
2.
Phase II Pilot Study of Tumor-Specific p53 or ras Vaccines With or Without Cellular Immunotherapy With Peptide-Activated Lymphocytes Plus Interleukin-2 in Patients With Tumors Expressing Mutant p53 or ras
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
NCI
NCI-95-C-0105A
NCI-T94-0096N, T94-0096, NCT00019084
Last Modified:
4/20/2007
3.
Phase II Study of Vaccine Therapy With Tumor-Specific Mutated Ras Peptides in Combination With Interleukin-2 and/or Sargramostim (GM-CSF) in Adults With Metastatic Solid Tumors
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Treatment
Completed
18 and over
NCI
NCI-97-C-0141F
NCI-T96-0078, T96-0078, NCT00019331
Last Modified:
4/20/2007
4.
Phase I Pilot Study of Adjuvant Vaccine Therapy With Tumor-Specific Mutated ras Peptides in Patients With Colorectal, Pancreatic, Lung, Breast, or Prostate Cancer (Summary Last Modified 05/2002)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
NCI
NCI-94-C-0096D
NCI-T93-0152N, T93-0152, NCT00019006
Last Modified:
3/1/1998
5.
Phase IB Study of Vaccination with a Recombinant Mutant ras Protein with the Immunologic Adjuvant QS21 in Patients with Adenocarcinomas Expressing an Activated ras Oncoprotein (Summary Last Modified 03/98)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
over 18
NCI
NCI-97-C-0018
CRB-9411, NCI-NMOB-9608, NCI-T95-0048N, T95-0048
Last Modified:
12/1/2001
 
First Published:
9/1/1999
6.
Phase I Pilot Study of Ras Peptide Cancer Vaccine in Patients with Myelodysplastic Syndrome (Summary Last Modified 12/2001)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Closed
Over 17
NCI
MSKCC-98037
NCI-G99-1542, NCT00003959
Last Modified:
9/1/2001
 
First Published:
5/1/2000
7.
Phase I Pilot Study of Ras Peptide Cancer Vaccine and Sargramostim (GM-CSF) in Patients With Stage IB-IV Non-Small Cell Lung Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
Over 17
NCI
MSKCC-99028
NCI-G00-1775, NCT00005630
Last Modified:
4/20/2007
 
First Published:
10/1/2000
8.
Phase I Study of Ras Peptide Cancer Vaccine Plus Immunological Adjuvant QS21 in Patients With Advanced Pancreatic or Colorectal Adenocarcinoma (Summary Last Modified 06/2002)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase I
Treatment
Completed
18 and over
NCI
FCCC-98026
NCI-T97-0051, NCT00006387, T97-0051
Select All on One Page
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute